FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:683-694 August 12, 2004 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Von Willebrand's disease is an inherited bleeding disorder with a prevalence as high as 1 to 2 percent in the general population, according to screening studies.^1,2 In contrast, estimates based on referral for symptoms of bleeding suggest a prevalence of 30 to 100 cases per million, which is similar to the prevalence of hemophilia A.^1,2 The disease was first described in 1926 by the Finnish pediatrician Erik von Willebrand, who used a rowboat to make house calls to patients with the disease in the Åland archipelago. The disease is caused by the quantitative deficiency or dysfunction of von Willebrand factor, . . . [Full Text of this Article]

Classification

Laboratory Diagnosis

General Principles of Treatment

Autologous Replacement Therapy

Dosage and Routes of Administration

Clinical Efficacy

Response and Phenotypes

Adverse Effects

Allogeneic Replacement Therapy

Replacement Products

Dosage of Concentrate

Laboratory Monitoring

Antifibrinolytic Amino Acids

Reproductive Health

Menorrhagia

Management of Delivery

Alloantibodies

Acquired von Willebrand Syndrome

The Future

Conclusions

Source Information

From the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and the Department of Internal Medicine and Dermatology, Istituto di Ricovero e Cura a Carattere Scientifico Maggiore Hospital and the University of Milan, Milan.

Address reprint requests to Dr. Mannucci at Via Pace 9, 20122 Milan, Italy, or at piermannuccio.mannucci@unimi.it.

Related Letters:

Treatment of von Willebrand's Disease
Kashyap A. S., Anand K. P., Kashyap S., Tanvetyanon T., Mannucci P.M.
Extract | Full Text | PDF  
N Engl J Med 2004; 351:2345-2346, Nov 25, 2004. Correspondence

This article has been cited by other articles:

• Cuker, A., Connors, J. M., Katz, J. T., Levy, B. D., Loscalzo, J. (2009). A Bloody Mystery. NEJM 361: 1887-1894 [Full Text]  
• Maquoi, I., Bonhomme, V., Born, J. D., Dresse, M.-F., Ronge-Collard, E., Minon, J.-M., Hans, P. (2009). Perioperative Management of a Child with von Willebrand Disease Undergoing Surgical Repair of Craniosynostosis: Looking at Unusual Targets. Anesth. Analg. 109: 720-724 [Abstract] [Full Text]  
• Rodeghiero, F., Castaman, G., Tosetto, A. (2009). How I treat von Willebrand disease. Blood 114: 1158-1165 [Abstract] [Full Text]  
• Lapecorella, M., Napoletano, M., Mariani, G., Mascaretti, G., Colageo, E. (2009). Bleeding Management of Uterine Conization Using a Pasteurized FVIII/VWF Concentrate in a Woman Affected by Type 2A von Willebrand Disease. CLIN APPL THROMB HEMOST 15: 245-246  
• Sucker, C., Scharf, R. E., Zotz, R. B. (2009). Use of Recombinant Factor VIIa in Inherited and Acquired von Willebrand Disease. CLIN APPL THROMB HEMOST 15: 27-31 [Abstract]  
• Czarnetzki, C., Elia, N., Lysakowski, C., Dumont, L., Landis, B. N., Giger, R., Dulguerov, P., Desmeules, J., Tramer, M. R. (2008). Dexamethasone and Risk of Nausea and Vomiting and Postoperative Bleeding After Tonsillectomy in Children: A Randomized Trial. JAMA 300: 2621-2630 [Abstract] [Full Text]  
• Davi, G., Patrono, C. (2007). Platelet Activation and Atherothrombosis. NEJM 357: 2482-2494 [Full Text]  
• Federici, A. B., Castaman, G., Franchini, M., Morfini, M., Zanon, E., Coppola, A., Tagliaferri, A., Boeri, E., Mazzucconi, M. G., Rossetti, G., Mannucci, P. M. (2007). Clinical use of Haemate(R) P in inherited von Willebrand's disease: a cohort study on 100 Italian patients. haematol 92: 944-951 [Abstract] [Full Text]  
• van Schooten, C. J. M., Denis, C. V., Lisman, T., Eikenboom, J. C. J., Leebeek, F. W., Goudemand, J., Fressinaud, E., van den Berg, H. M., de Groot, P. G., Lenting, P. J. (2007). Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels. Blood 109: 2430-2437 [Abstract] [Full Text]  
• Ozgonenel, B., Rajpurkar, M., Lusher, J. M (2007). How do you treat bleeding disorders with desmopressin?. Postgrad. Med. J. 83: 159-163 [Abstract] [Full Text]  
• Michiels, J. J., van Vliet, H. H. D. M., Berneman, Z., Gadisseur, A., van der Planken, M., Schroyens, W., van der Velden, A., Budde, U. (2007). Intravenous DDAVP and Factor VIII-von Willebrand Factor Concentrate for the Treatment and Prophylaxis of Bleedings in Patients With von Willebrand Disease Type 1, 2 and 3. CLIN APPL THROMB HEMOST 13: 14-34 [Abstract]  
• Crowther, M. A., Abshire, T. C. (2007). Hemostasis and thrombosis. ASH-SAP 2007: 361-407 [Full Text]  
• Riddel, J. P. Jr., Aouizerat, B. E. (2006). Genetics of von Willebrand disease type 1.. Biol Res Nurs 8: 147-156 [Abstract]  
• Pergolizzi, R. G., Jin, G., Chan, D., Pierre, L., Bussel, J., Ferris, B., Leopold, P. L., Crystal, R. G. (2006). Correction of a murine model of von Willebrand disease by gene transfer. Blood 108: 862-869 [Abstract] [Full Text]  
• Pruthi, R. K. (2006). A Practical Approach to Genetic Testing for von Willebrand Disease. Mayo Clin Proc. 81: 679-691 [Abstract] [Full Text]  
• Nakamura, F., Pudas, R., Heikkinen, O., Permi, P., Kilpelainen, I., Munday, A. D., Hartwig, J. H., Stossel, T. P., Ylanne, J. (2006). The structure of the GPIb-filamin A complex. Blood 107: 1925-1932 [Abstract] [Full Text]  
• James, A. H., Ragni, M. V., Picozzi, V. J. (2006). Bleeding Disorders in Premenopausal Women: (Another) Public Health Crisis for Hematology?. ASH Education Book 2006: 474-485 [Abstract] [Full Text]  
• Kashyap, A. S., Anand, K. P., Kashyap, S., Tanvetyanon, T., Mannucci, P.M. (2004). Treatment of von Willebrand's Disease. NEJM 351: 2345-2346 [Full Text]